Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy

International Journal of Clinical Practice

Volumn 60, Issue 4, 2006, Pages 500-503

  Gorkin, Larry ^a   Hvidsten, K ^a   Sobel, R E ^a   Siegel, R ^a  

^a PFIZER INC   (United States)

Author keywords

Diabetes; Erectile dysfunction; Hypertension; Ischemic; Optic neuropathy; Phosphodiesterase type 5 inhibitors; Sildenafil citrate

Indexed keywords

NITRATE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EXPOSURE; DRUG INFORMATION; DRUG MARKETING; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INCIDENCE; INDUCED HYPOTENSION; ISCHEMIA; ISCHEMIC OPTIC NEUROPATHY; MALE; NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK FACTOR; VISUAL IMPAIRMENT;

AGED; ERECTILE DYSFUNCTION; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; OPTIC NEUROPATHY, ISCHEMIC; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RISK FACTORS; SULFONES;

EID: 33645052699     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00904.x     Document Type: Article

References (25)

1. Hattenhauer MG, Leavitt JA, Hodge DO et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997; 123: 103-7.
2. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994; 14: 38-44.
3. Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr Opin Neurol 2004; 17: 27-35.
4. Newman NJ, Scherer R, Langenberg P et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002; 134: 317-28.
5. The Ischemic Optic Neuropathy Decompression Trial Research Group. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114: 1366-74.
6. Burde RM. Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1993; 116: 759-64.
7. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171: 2341-5.
8. Feldman HA, Johannes CB, Derby CA et al. Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts male aging study. Prev Med 2000; 30: 328-38.
9. Roumeguere T, Wespes E, Carpentier Y et al. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003; 44: 355-9.
10. Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in prevalence, treatment, and control of hypertension - United States, 1999-2002. MMWR Morb Mortal Wkly Rep 2005; 54: 7-9.
11. Annis AM, Caulder MS, Cook ML et al. Family history, diabetes, and other demographic and risk factors among participants of the National Health and Nutrition Examination Survey 1999-2002. Prev Chronic Dis [serial online] 2005 April [date cited] (retrieved from http://www.cdc.gov/pcd/ issues/2005/apr/04_0131.htm.2005).
12. Hayreh SS, Joos KM, Podhajsky PA et al. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 118: 766-80.
13. National Center for Health Statistics. National Health and Nutritional Examination Survey (NHANES). http://www.cdc.gov/nchs/nhanes.htm (accessed on December 20, 2005).
14. Data on file. Pfizer Inc, New York, NY, 2005.
15. Tran D, Howes L. Cardiovascular safety of sildenafil. Drug Saf 2003; 26: 453-60.
16. Padma-Nathan H, Eardley I, Kloner RA et al. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002; 60 (Suppl. 2B): 67-90.
17. Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol 2005; 96: 443-6.
18. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003; 57: 597-600.
19. VIAGRA® (sildenafil citrate). Full Prescribing Information. Pfizer Inc, New York, NY 2005.
20. REVATIO® (sildenafil citrate). Full Prescribing Information. Pfizer Inc, New York, NY 2005.
21. Giuliano F, Porst H, Hedelin H et al. Cardiovascular safety of Viagra® (sildenafil citrate): Results of the international men's health study. Eur Urol 2005; 4 (Suppl. 3): 137.
22. Shakir SAW, Wilton LV, Heeley E et al. Sildenafil prescription-event monitoring study. No evidence of an increase in cardiovascular outcomes among 5,000 men prescribed sildenafil in general practice in England. J Am Coll Cardiol 2001; 37: 299A.
23. Shakir SAW, Wilton LV, Boshier A et al. Cardiovascular events in users of sildenafil: Results from first phase of prescription event monitoring in England. BMJ 2001; 322: 651-2.
24. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: Experience gained in general practice use in England in 1999. BJU Int 2004; 93: 796-801.
25. Boshier A, Pambakian N, Shakir SA. A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil. Int J Clin Pharmacol Ther 2002; 40: 422-3.